C07C 307/06
Having nitrogen atoms of the sulfamide groups bound to acyclic carbon atoms
Official title: having nitrogen atoms of the sulfamide groups bound to acyclic carbon atoms
C07C307/06 (Having nitrogen atoms of the sulfamide groups bound to acyclic carbon atoms) appears on 136 US grants and 125 published applications in this corpus.
Search patents in C07C- Granted patents
- 136
- Published applications
- 125
- Assignees
- 96
- Inventors
- 441
- Latest grant
- 21 Apr 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1977 | 1 | 0 |
| 1978 | 6 | 0 |
| 1979 | 0 | 0 |
| 1980 | 0 | 0 |
| 1981 | 0 | 0 |
| 1982 | 0 | 0 |
| 1983 | 0 | 0 |
| 1984 | 0 | 0 |
| 1985 | 0 | 0 |
| 1986 | 0 | 0 |
| 1987 | 0 | 0 |
| 1988 | 0 | 0 |
| 1989 | 0 | 0 |
| 1990 | 0 | 0 |
| 1991 | 1 | 0 |
| 1992 | 0 | 0 |
| 1993 | 3 | 0 |
| 1994 | 4 | 0 |
| 1995 | 1 | 0 |
| 1996 | 6 | 0 |
| 1997 | 2 | 0 |
| 1998 | 3 | 0 |
| 1999 | 3 | 0 |
| 2000 | 7 | 0 |
| 2001 | 6 | 0 |
| 2002 | 11 | 6 |
| 2003 | 6 | 8 |
| 2004 | 1 | 10 |
| 2005 | 4 | 3 |
| 2006 | 6 | 6 |
| 2007 | 9 | 7 |
| 2008 | 0 | 4 |
| 2009 | 2 | 3 |
| 2010 | 2 | 11 |
| 2011 | 1 | 3 |
| 2012 | 4 | 7 |
| 2013 | 8 | 8 |
| 2014 | 5 | 4 |
| 2015 | 9 | 6 |
| 2016 | 2 | 4 |
| 2017 | 1 | 2 |
| 2018 | 4 | 5 |
| 2019 | 3 | 2 |
| 2020 | 2 | 4 |
| 2021 | 2 | 4 |
| 2022 | 2 | 0 |
| 2023 | 1 | 9 |
| 2024 | 4 | 3 |
| 2025 | 3 | 4 |
| 2026 | 1 | 2 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Calpain-2 inhibitor compounds and methods of treatment21 Apr 2026US 12,606,520 B2Western University of Health Sciences
- Urea compound for antagonizing LPA1 receptor24 Jun 2025US 12,338,203 B2Taisho Pharmaceutical Co., Ltd.
- Compounds and compositions for intracellular delivery of therapeutic agents10 Jun 2025US 12,324,859 B2ModernaTX, Inc.
- Gamma-hydroxybutyrate delivering compounds and processes for making and using them18 Mar 2025US 12,251,445 B2Zevra Therapeutics, Inc.
- Electrolyte solution additive containing isocyanate and sulfamide structural groups and application thereof10 Dec 2024US 12,166,176 B2Valiant Corporation
- Compounds and compositions for treating conditions associated with nlrp activity16 Jul 2026US 2026/0200880 A1Novartis AG
- Compounds and compositions for intracellular delivery of therapeutic agents12 Mar 2026US 2026/0069549 A1ModernaTX, Inc.
- Gamma-hydroxybutyrate delivering compounds and processes for making and using them4 Dec 2025US 2025/0367299 A1Zevra Therapeutics, Inc.
- Covalent fluorescent probes for cannabinoid receptor 223 Oct 2025US 2025/0325711 A1Hoffmann-La Roche Inc.
- Gamma-hydroxybutyrate delivering compounds and processes for making and using them12 Jun 2025US 2025/0186591 A1Zevra Therapeutics, Inc.
Most cited
By later US patents
- Sulfonamide inhibitors of aspartyl protease147US 5,585,397 AVertex Pharmaceuticals Incorporated · 1996
- Conformationally restricted aromatic inhibitors of microsomal triglyceride transfer protein and method125US 5,760,246 A1998
- Compounds and compositions for intracellular delivery of therapeutic agents88US 10,857,105 B2MordernaTX, Inc. · 2020
- Sulfonamide inhibitors of aspartyl protease50US 6,372,778 B1Vertex Pharmaceuticals Incorporated · 2002
- N-substituted benzamides and methods of use thereof50US 8,933,236 B2Genentech, Inc. · 2015